Concentrated sesame seed compounds lower the upper blood-pressure number by a few points; blood-fat findings disagree; blood-sugar markers improve in a few small trials. They also slow the body's breakdown of vitamin E. Safety is dominated by sesame allergy, plus blocking of a liver enzyme that clears many medicines. A low-cost, low-risk addition with a modest, genuinely uncertain payoff. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Systolic / Diastolic Blood Pressure | 110–120 / 70–75 mmHg | Primary endpoint with the most consistent trial support |
| LDL Cholesterol | < 80 mg/dL | Tracks the conflicted lipid benefit |
| Triglycerides | < 80 mg/dL | The most consistent lipid response across pooled analyses |
| HbA1c | 4.8–5.4% | Captures the glycemic signal over a 3-month window |
| Fasting Glucose | 75–90 mg/dL | Detects the shorter-term glucose response |
| hs-CRP | < 0.5 mg/L | Tests whether the anti-inflammatory signal applies to the individual |
| ALT and AST | ALT 10–26 U/L (men), 10–19 U/L (women); AST 10–26 U/L | Confirms the liver tolerates the enzyme-inhibiting load |
| Serum Gamma-Tocopherol | No established target; track the change from the individual's own baseline | Confirms the vitamin E–sparing mechanism is active |
| Sesame-Specific IgE | < 0.35 kU/L (undetectable) | Screens for the allergy risk that dominates this intervention |
Cadence: Baseline panel before starting; sesame-specific IgE at baseline only where there is a seed or nut allergy history. Blood pressure at home daily for two weeks, then weekly. Bloodwork repeats at 8 weeks, then every 6–12 months once a stable response is established. On warfarin or a narrow-margin CYP3A4 substrate, drug-level or clotting checks at 1 and 4 weeks.